{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:01:07Z","timestamp":1793239267138,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015183","name":"Immunodiagnostic Systems Holdings","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015183","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.cca.2020.12.023","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T11:30:33Z","timestamp":1609155033000},"page":"16-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"special_numbering":"C","title":["Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and \u03b2-CTX in blood"],"prefix":"10.1016","volume":"515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-0065","authenticated-orcid":false,"given":"Harjit P.","family":"Bhattoa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-2226","authenticated-orcid":false,"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6712-9955","authenticated-orcid":false,"given":"Annemieke C.","family":"Heijboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9624-5210","authenticated-orcid":false,"given":"Niklas R.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-9028","authenticated-orcid":false,"given":"Konstantinos","family":"Makris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-6873","authenticated-orcid":false,"given":"Candice Z.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart L.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel D.","family":"Vasikaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2020.12.023_b0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","article-title":"Diagnosis, prophylaxis, and treatment of osteoporosis","volume":"94","author":"Consensus Development Conference","year":"1993","journal-title":"Am. J. Med."},{"key":"10.1016\/j.cca.2020.12.023_b0010","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1007\/s00198-011-1596-z","article-title":"Geographic trends in incidence of hip fractures: a comprehensive literature review","volume":"22","author":"Cheng","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.cca.2020.12.023_b0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bone.2007.11.001","article-title":"A reference standard for the description of osteoporosis","volume":"42","author":"Kanis","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.cca.2020.12.023_b0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11914-009-0013-4","article-title":"From relative risk to absolute fracture risk calculation: the FRAX algorithm","volume":"7","author":"McCloskey","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.cca.2020.12.023_b0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.cca.2020.12.023_b0030","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"Diagnosis of endocrine disease: Bone turnover markers: are they clinically useful?","volume":"178","author":"Eastell","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.cca.2020.12.023_b0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.cca.2020.12.023_b0040","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","article-title":"Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis","volume":"36","author":"Lorentzon","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.cca.2020.12.023_b0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.cca.2020.12.023_b0050","series-title":"Osteoporosis: Etiology, Diagnosis and Management","first-page":"95","article-title":"The biochemistry of bone","author":"Robey","year":"1988"},{"key":"10.1016\/j.cca.2020.12.023_b0055","first-page":"333","article-title":"Molecular basis and clinical application of biological markers of bone turnover","volume":"17","author":"Calvo","year":"1996","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.cca.2020.12.023_b0060","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1146\/annurev.bi.53.070184.003441","article-title":"Cross-linking in collagen and elastin","volume":"53","author":"Eyre","year":"1984","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.cca.2020.12.023_b0065","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/j.1699-0463.1992.tb04047.x","article-title":"Fetal antigen 2: an amniotic protein identified as the aminopropeptide of the alpha 1 chain of human procollagen type I","volume":"100","author":"Teisner","year":"1992","journal-title":"APMIS"},{"key":"10.1016\/j.cca.2020.12.023_b0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0028-2243(88)90167-0","article-title":"Two fetal antigens (FA-1 and FA-2) and endometrial proteins (PP12 and PP14) isolated from amniotic fluid; preliminary observations in fetal and maternal tissues","volume":"29","author":"Fay","year":"1988","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.cca.2020.12.023_b0075","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/8756-3282(96)00165-2","article-title":"Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism","volume":"19","author":"Orum","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.cca.2020.12.023_b0080","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0009-8981(94)90125-2","article-title":"Development of a radioimmunoassay for fetal antigen 2","volume":"224","author":"Price","year":"1994","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2020.12.023_b0085","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/clinchem\/42.6.947","article-title":"Immunoassay for intact amino-terminal propeptide of human type I procollagen","volume":"42","author":"Melkko","year":"1996","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0009-8981(97)00182-4","article-title":"Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms","volume":"269","author":"Jensen","year":"1998","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2020.12.023_b0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinchem\/45.1.47","article-title":"Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology","volume":"45","author":"Brandt","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0100","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0009-9120(96)00134-8","article-title":"The aminoterminal propeptide of type I procollagen: evaluation of a commercial radioimmunoassay kit and values in healthy subjects","volume":"30","author":"Tahtela","year":"1997","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2020.12.023_b0105","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.clinbiochem.2010.09.019","article-title":"Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay","volume":"43","author":"Koivula","year":"2010","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.cca.2020.12.023_b0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1373\/clinchem.2007.094953","article-title":"Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis","volume":"54","author":"Garnero","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0115","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1093\/clinchem\/40.11.2022","article-title":"Immunoassay for quantifying type I collagen degradation products in urine evaluated","volume":"40","author":"Bonde","year":"1994","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0120","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0125","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"National Bone Health Alliance Bone Turnover Marker Project. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.cca.2020.12.023_b0130","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1359\/jbmr.1997.12.7.1028","article-title":"Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen","volume":"12","author":"Bonde","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.cca.2020.12.023_b0135","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/clinchem\/48.4.671","article-title":"Serum CrossLaps: pediatric reference intervals from birth to 19 years of age","volume":"48","author":"Crofton","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0140","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.bone.2009.07.089","article-title":"A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy","volume":"45","author":"Rogers","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.cca.2020.12.023_b0145","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2020.12.023_b0150","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.bone.2010.04.325","article-title":"A new \u03b2-crosslaps\u00ae (CTX-I) assay on the IDS-ISYS automated analyser","volume":"47","author":"Seres","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.cca.2020.12.023_b0155","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1515\/cclm-2019-0174","article-title":"IFCC-IOF Joint Committee for Bone Metabolism (C-BM). A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism","volume":"57","author":"Cavalier","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2020.12.023_b0160","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1007\/s00198-017-4026-z","article-title":"Comparison of two automated assays of BTM (CTX and PINP) and reference intervals in a Danish population","volume":"28","author":"J\u00f8rgensen","year":"2017","journal-title":"Osteoporos. Int."},{"issue":"47","key":"10.1016\/j.cca.2020.12.023_b0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1258\/acb.2009.009110","article-title":"Difference between total and intact assays for N-terminalpropeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide","volume":"47","author":"Koivula","year":"2010","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.cca.2020.12.023_b0170","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1515\/cclm-2012-0531","article-title":"IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children","volume":"51","author":"Morovat","year":"2013","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2020.12.023_b0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2013.07.016","article-title":"Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters","volume":"425","author":"Cavalier","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2020.12.023_b0180","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1515\/cclm-2013-0934","article-title":"Method-specific differences in beta-isomerised carboxy-terminal cross-linking telopeptide of type I collagen and procollagen type I amino-terminal propeptide using two fully automated immunoassays","volume":"52","author":"Wheater","year":"2014","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2020.12.023_b0185","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00198-020-05310-6","article-title":"Harmonization of commercial assays for PINP; the way forward","volume":"31","author":"Vasikaran","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.cca.2020.12.023_b0190","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clinbiochem.2015.03.002","article-title":"Comparison of results from commercial assays for plasma CTX: The need for harmonization","volume":"48","author":"Chubb","year":"2015","journal-title":"Clin. Biochem."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812030591X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000989812030591X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:04:02Z","timestamp":1762113842000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000989812030591X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":38,"alternative-id":["S000989812030591X"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.023","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and \u03b2-CTX in blood","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}